Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

@article{Mpagama2014PlasmaDA,
  title={Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.},
  author={Stellah G Mpagama and Norah Ndusilo and Suzanne E. Stroup and Happiness H Kumburu and Charles A Peloquin and Jean Gratz and Eric R Houpt and Gibson S. Kibiki and Scott K. Heysell},
  journal={Antimicrobial agents and chemotherapy},
  year={2014},
  volume={58 2},
  pages={
          782-8
        }
}
Little is known about plasma drug concentrations relative to quantitative susceptibility in patients with multidrug-resistant tuberculosis (MDR-TB). We previously described a TB drug activity (TDA) assay that determines the ratio of the time to detection of plasma-cocultured Mycobacterium tuberculosis versus control growth in a Bactec MGIT system. Here, we assess the activity of individual drugs in a typical MDR-TB regimen using the TDA assay. We also examined the relationship of the TDA to the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Diagnostic Opportunities for Optimizing Management of Multidrug-Resistant Tuberculosis (MDR-TB) in Tanzania

  • Stellah GMpagamaa
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Towards individualised treatment of tuberculosis

VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance.

VIEW 1 EXCERPT

Evaluation of the Sensititre MYCOTB plate for the susceptibility testing of Mycobacterium tuberculosis complex against first and second line agents

  • C Scarporo, P Ricordio, G Rugerio, P Piccoli
  • J . Clin . Microbiol .
  • 2012

Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.